22 Points to Consider for Clinical Trials in Systemic Sclerosis
Recently a study identified by disease marker, the scleroderma patients best and least suited to take part in clinical trials. In this Oxford Academic (Oxford University Press) video, watch Professor Chris Denton talk about his article: ‘Twenty-two Points to Consider for Clinical Trials…